1-17 of 17
Thomas Powles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

Christopher J. Sweeney, Russell Petry, Chang Xu, Merrida Childress, Jie He, David Fabrizio, Ole Gjoerup, Samantha Morley, Timothy Catlett, Zoe J. Assaf, Kobe Yuen, Matthew Wongchenko, Kalpit Shah, Pratyush Gupta, Priti Hegde, Lincoln W. Pasquina, Sanjeev Mariathasan, Ryon P. Graf, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4115–4122.
https://doi.org/10.1158/1078-0432.CCR-24-1096
Published: 13 September 2024
View article titled, Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy

Vishwani Chauhan, Sofia Silva Diaz, Pablo Jara, Denis Efovi, Ayushma Gurung, Matthew Young, Connor Wells, Elizabeth Nally, Bernadett Szabados, Thomas Powles, Francesca Jackson-Spence
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10_Supplement): B013.
https://doi.org/10.1158/1557-3265.BLADDER24-B013
Published: 17 May 2024
View article titled, Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy
Journal Articles

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, Juan Martin-Liberal, Sang Joon Shin, Terence Friedlander, Diego Tosi, Chandler Park, Carlos Gomez-Roca, Florence Joly Lobbedez, Daniel Castellano, Rafael Morales-Barrera, Irene Moreno-Candilejo, Aude Fléchon, Kobe Yuen, Deepali Rishipathak, Kelly DuPree, Fiona Young, Francesca Michielin, Colby S. Shemesh, Elizabeth E. Steinberg, Patrick Williams, Jae Lyun Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4373–4384.
https://doi.org/10.1158/1078-0432.CCR-23-0798
Published: 01 November 2023
View article titled, Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Open the PDF for Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma) in another window
Includes: Supplementary data
Journal Articles

Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)

Bernadett Szabados, Mariano Ponz-Sarvisé, Robson Machado, Diego Saldana, Edward E. Kadel, Romain Banchereau, Fanny Bouquet, Marius Garmhausen, Thomas Powles, Carsten Schröder, On Behalf of the imCORE Working Group of Early Career Investigators (imFLAME)
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4083–4091.
https://doi.org/10.1158/1078-0432.CCR-22-0200
Published: 15 September 2022
View article titled, Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
Open the PDF for Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI) in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, III, Sanjeev Mariathasan, Carol O'Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3360–3369.
https://doi.org/10.1158/1078-0432.CCR-20-1981
Published: 15 June 2021
View article titled, Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Open the PDF for Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jeronimo R. Rodriguez-Cid, Sumanta K. Pal, Andre M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 78–86.
https://doi.org/10.1158/1078-0432.CCR-20-2063
Published: 04 January 2021
View article titled, Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Open the PDF for Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy

Daniel Petrylak, Jonathan Rosenberg, Ignacio Duran, Yohann Loriot, Guru Sonpavde, Chunzhang Wu, Elaina Gartner, Amal Melhem- Bertrandt, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): B26.
https://doi.org/10.1158/1557-3265.BLADDER19-B26
Published: 03 August 2020
View article titled, Abstract B26: EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy
Journal Articles

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Michael B. Atkins, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, Carsten Grüllich, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piault-Louis, Christina Schiff, Bernard Escudier
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2506–2514.
https://doi.org/10.1158/1078-0432.CCR-19-2838
Published: 01 June 2020
View article titled, Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Open the PDF for Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Abdallah Flaifel, Wanling Xie, David A. Braun, Miriam Ficial, Ziad Bakouny, Amin H. Nassar, Rebecca B. Jennings, Bernard Escudier, Daniel J. George, Robert J. Motzer, Michael J. Morris, Thomas Powles, Evelyn Wang, Ying Huang, Gordon J. Freeman, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6080–6088.
https://doi.org/10.1158/1078-0432.CCR-19-1135
Published: 15 October 2019
View article titled, PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Open the PDF for PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN in another window
Includes: Supplementary data
Journal Articles

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

Chun-Fang Xu, Toby Johnson, Xiaojing Wang, Chris Carpenter, Alan P. Graves, Liling Warren, Zhengyu Xue, Karen S. King, Dana J. Fraser, Sandy Stinnett, Linda P. Briley, Ionel Mitrica, Colin F. Spraggs, Matthew R. Nelson, Hiroomi Tada, Andreas du Bois, Thomas Powles, Neil Kaplowitz, Lini N. Pandite
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1371–1377.
https://doi.org/10.1158/1078-0432.CCR-15-2044
Published: 14 March 2016
View article titled, <em>HLA-B</em>*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Open the PDF for <em>HLA-B</em>*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer in another window
Includes: Supplementary data
Journal Articles

Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer

Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, Lel Eory, Alexander L.R. Lubbock, Alan Mackay, Jyoti Nanda, Marie O'Donnell, Peter Mullen, S. Alan McNeill, Antony C.P. Riddick, Daniel Berney, Axel Bex, Michael Aitchison, Ian M. Overton, David J. Harrison, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4212–4223.
https://doi.org/10.1158/1078-0432.CCR-15-0207
Published: 14 September 2015
View article titled, Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
Open the PDF for Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer in another window
Includes: Supplementary data
Journal Articles

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, Robert J. Motzer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1071–1077.
https://doi.org/10.1158/1078-0432.CCR-14-1993
Published: 01 March 2015
View article titled, Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Open the PDF for Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study

Jonathan Shamash, Jimmy Jacob, Samir Agrawal, Thomas Powles, Katherine Mutsvangwa, Peter Wilson, Justin Stebbing
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2352–2359.
https://doi.org/10.1158/1078-0432.CCR-11-3293
Published: 16 April 2012
View article titled, Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study
Open the PDF for Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study in another window
Journal Articles

Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer

Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, Thomas Powles
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6021–6028.
https://doi.org/10.1158/1078-0432.CCR-10-3309
Published: 14 September 2011
View article titled, Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
Open the PDF for Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer in another window
Includes: Supplementary data